|
Gene: SEC24C |
Gene summary for SEC24C |
Gene summary. |
Gene information | Species | Human | Gene symbol | SEC24C | Gene ID | 9632 |
Gene name | SEC24 homolog C, COPII coat complex component | |
Gene Alias | SEC24C | |
Cytomap | 10q22.2 | |
Gene Type | protein-coding | GO ID | GO:0001701 | UniProtAcc | A0A024QZM6 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9632 | SEC24C | LZE20T | Human | Esophagus | ESCC | 4.80e-02 | 3.98e-02 | 0.0662 |
9632 | SEC24C | LZE22T | Human | Esophagus | ESCC | 2.91e-05 | 2.83e-01 | 0.068 |
9632 | SEC24C | LZE24T | Human | Esophagus | ESCC | 6.68e-16 | 4.16e-01 | 0.0596 |
9632 | SEC24C | P1T-E | Human | Esophagus | ESCC | 1.62e-04 | 2.16e-01 | 0.0875 |
9632 | SEC24C | P2T-E | Human | Esophagus | ESCC | 2.71e-16 | 2.74e-01 | 0.1177 |
9632 | SEC24C | P4T-E | Human | Esophagus | ESCC | 3.71e-14 | 2.30e-01 | 0.1323 |
9632 | SEC24C | P5T-E | Human | Esophagus | ESCC | 6.11e-12 | 9.56e-02 | 0.1327 |
9632 | SEC24C | P8T-E | Human | Esophagus | ESCC | 2.69e-14 | 2.41e-01 | 0.0889 |
9632 | SEC24C | P10T-E | Human | Esophagus | ESCC | 1.37e-11 | 2.03e-01 | 0.116 |
9632 | SEC24C | P11T-E | Human | Esophagus | ESCC | 5.04e-07 | 1.86e-01 | 0.1426 |
9632 | SEC24C | P12T-E | Human | Esophagus | ESCC | 9.93e-15 | 3.17e-01 | 0.1122 |
9632 | SEC24C | P15T-E | Human | Esophagus | ESCC | 6.64e-16 | 2.82e-01 | 0.1149 |
9632 | SEC24C | P16T-E | Human | Esophagus | ESCC | 7.87e-15 | 2.89e-01 | 0.1153 |
9632 | SEC24C | P17T-E | Human | Esophagus | ESCC | 2.63e-08 | 3.08e-01 | 0.1278 |
9632 | SEC24C | P19T-E | Human | Esophagus | ESCC | 2.05e-06 | 3.84e-01 | 0.1662 |
9632 | SEC24C | P20T-E | Human | Esophagus | ESCC | 1.31e-09 | 2.28e-01 | 0.1124 |
9632 | SEC24C | P21T-E | Human | Esophagus | ESCC | 5.02e-20 | 4.37e-01 | 0.1617 |
9632 | SEC24C | P22T-E | Human | Esophagus | ESCC | 7.41e-06 | 1.02e-01 | 0.1236 |
9632 | SEC24C | P23T-E | Human | Esophagus | ESCC | 3.34e-15 | 3.09e-01 | 0.108 |
9632 | SEC24C | P24T-E | Human | Esophagus | ESCC | 1.75e-13 | 2.56e-01 | 0.1287 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000690019 | Oral cavity | OSCC | vesicle budding from membrane | 49/7305 | 61/18723 | 4.73e-11 | 1.50e-09 | 49 |
GO:00901145 | Oral cavity | OSCC | COPII-coated vesicle budding | 24/7305 | 29/18723 | 1.74e-06 | 2.26e-05 | 24 |
GO:00901103 | Oral cavity | OSCC | COPII-coated vesicle cargo loading | 11/7305 | 15/18723 | 7.49e-03 | 2.75e-02 | 11 |
GO:004819316 | Oral cavity | LP | Golgi vesicle transport | 141/4623 | 296/18723 | 6.11e-18 | 1.06e-15 | 141 |
GO:001605013 | Oral cavity | LP | vesicle organization | 128/4623 | 300/18723 | 4.96e-12 | 3.98e-10 | 128 |
GO:000688814 | Oral cavity | LP | endoplasmic reticulum to Golgi vesicle-mediated transport | 67/4623 | 130/18723 | 3.74e-11 | 2.39e-09 | 67 |
GO:000170117 | Oral cavity | LP | in utero embryonic development | 142/4623 | 367/18723 | 1.48e-09 | 6.75e-08 | 142 |
GO:0006900110 | Oral cavity | LP | vesicle budding from membrane | 36/4623 | 61/18723 | 1.19e-08 | 4.50e-07 | 36 |
GO:009011413 | Oral cavity | LP | COPII-coated vesicle budding | 18/4623 | 29/18723 | 2.15e-05 | 3.51e-04 | 18 |
Page: 1 2 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04141211 | Esophagus | ESCC | Protein processing in endoplasmic reticulum | 147/4205 | 174/8465 | 3.29e-22 | 1.10e-19 | 5.64e-20 | 147 |
hsa05130211 | Esophagus | ESCC | Pathogenic Escherichia coli infection | 142/4205 | 197/8465 | 8.21e-11 | 1.06e-09 | 5.42e-10 | 142 |
hsa04141310 | Esophagus | ESCC | Protein processing in endoplasmic reticulum | 147/4205 | 174/8465 | 3.29e-22 | 1.10e-19 | 5.64e-20 | 147 |
hsa05130310 | Esophagus | ESCC | Pathogenic Escherichia coli infection | 142/4205 | 197/8465 | 8.21e-11 | 1.06e-09 | 5.42e-10 | 142 |
hsa0414122 | Liver | HCC | Protein processing in endoplasmic reticulum | 146/4020 | 174/8465 | 7.34e-24 | 2.46e-21 | 1.37e-21 | 146 |
hsa0513042 | Liver | HCC | Pathogenic Escherichia coli infection | 129/4020 | 197/8465 | 2.02e-07 | 2.50e-06 | 1.39e-06 | 129 |
hsa0414132 | Liver | HCC | Protein processing in endoplasmic reticulum | 146/4020 | 174/8465 | 7.34e-24 | 2.46e-21 | 1.37e-21 | 146 |
hsa0513052 | Liver | HCC | Pathogenic Escherichia coli infection | 129/4020 | 197/8465 | 2.02e-07 | 2.50e-06 | 1.39e-06 | 129 |
hsa0414130 | Oral cavity | OSCC | Protein processing in endoplasmic reticulum | 143/3704 | 174/8465 | 6.82e-26 | 2.28e-23 | 1.16e-23 | 143 |
hsa0513030 | Oral cavity | OSCC | Pathogenic Escherichia coli infection | 129/3704 | 197/8465 | 4.32e-10 | 5.17e-09 | 2.63e-09 | 129 |
hsa04141113 | Oral cavity | OSCC | Protein processing in endoplasmic reticulum | 143/3704 | 174/8465 | 6.82e-26 | 2.28e-23 | 1.16e-23 | 143 |
hsa05130114 | Oral cavity | OSCC | Pathogenic Escherichia coli infection | 129/3704 | 197/8465 | 4.32e-10 | 5.17e-09 | 2.63e-09 | 129 |
hsa04141210 | Oral cavity | LP | Protein processing in endoplasmic reticulum | 113/2418 | 174/8465 | 8.74e-24 | 5.82e-22 | 3.76e-22 | 113 |
hsa05130210 | Oral cavity | LP | Pathogenic Escherichia coli infection | 87/2418 | 197/8465 | 1.71e-06 | 1.78e-05 | 1.15e-05 | 87 |
hsa0414138 | Oral cavity | LP | Protein processing in endoplasmic reticulum | 113/2418 | 174/8465 | 8.74e-24 | 5.82e-22 | 3.76e-22 | 113 |
hsa0513038 | Oral cavity | LP | Pathogenic Escherichia coli infection | 87/2418 | 197/8465 | 1.71e-06 | 1.78e-05 | 1.15e-05 | 87 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SEC24C | SNV | Missense_Mutation | rs755761928 | c.614N>T | p.Ser205Phe | p.S205F | P53992 | protein_coding | deleterious(0.04) | benign(0.05) | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SEC24C | SNV | Missense_Mutation | c.1521N>C | p.Met507Ile | p.M507I | P53992 | protein_coding | tolerated(0.08) | benign(0.073) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
SEC24C | SNV | Missense_Mutation | c.3230N>T | p.Ser1077Phe | p.S1077F | P53992 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AR-A1AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
SEC24C | SNV | Missense_Mutation | c.2113N>A | p.Asp705Asn | p.D705N | P53992 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0DH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
SEC24C | SNV | Missense_Mutation | c.1330C>A | p.Arg444Ser | p.R444S | P53992 | protein_coding | deleterious(0) | possibly_damaging(0.495) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SEC24C | SNV | Missense_Mutation | c.1359N>G | p.Ile453Met | p.I453M | P53992 | protein_coding | deleterious(0.01) | benign(0.238) | TCGA-C8-A12T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SEC24C | SNV | Missense_Mutation | c.263N>G | p.Gln88Arg | p.Q88R | P53992 | protein_coding | deleterious(0.01) | benign(0.165) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD | |
SEC24C | SNV | Missense_Mutation | rs780721252 | c.2201N>A | p.Arg734Gln | p.R734Q | P53992 | protein_coding | tolerated(0.36) | benign(0.205) | TCGA-S3-AA10-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR |
SEC24C | insertion | Frame_Shift_Ins | rs764652839 | c.1368_1369insC | p.Gln459ProfsTer17 | p.Q459Pfs*17 | P53992 | protein_coding | TCGA-A2-A0T2-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | xeloda | PD | ||
SEC24C | insertion | Frame_Shift_Ins | novel | c.324_325insGGAGA | p.Pro109GlyfsTer120 | p.P109Gfs*120 | P53992 | protein_coding | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |